AllDocs -> cancers

Cancer Mortality by Proportion Indigenous Population in Queensland Uterine cancer 0 3 6 9 12 15 Rate per 100,000 population Avg No. per Year Mortality of Uterine cancer among Females, by Indigenous Proportion, Queensland, Five Year Average, 1997 to 2001 2.6 43 <5% Indigenous Proportion Indigenous Population 3.6 5 At least 5% Indigenous Note: Rates are age standardised to the Australian population as at 30 June 2001. Numbers and rates are averaged over five years, and based on place of usual residence at time of diagnosis. The range shown by the orange line corresponds to the 95% confidence interval for the estimated rate. Uterine cancer is defined by the ICD-0-2 codes of C54 . Source: Queensland Cancer Registry, Queensland Health and Queensland Cancer ...

Cancer Incidence by Proportion Indigenous Population in Queensland Uterine cancer 0 3 6 9 12 15 18 Rate per 100,000 population Avg No. per Year Incidence of Uterine cancer among Females, by Indigenous Proportion, Queensland, Five Year Average, 1997 to 2001 15.9 246 <5% Indigenous Proportion Indigenous Population 14.1 20 At least 5% Indigenous Note: Rates are age standardised to the Australian population as at 30 June 2001. Numbers and rates are averaged over five years, and based on place of usual residence at time of diagnosis. The range shown by the orange line corresponds to the 95% confidence interval for the estimated rate. Uterine cancer is defined by the ICD-0-2 codes of C54 . Source: Queensland Cancer Registry, Queensland Health and Queensland ...

Trends in Cancer Mortality by Health Zone in Queensland Uterine cancer Rate per 100,000 population Mortality of Uterine cancer among Females, by Health Zone, Queensland, 1986 to 2001 Northern Central Southern 0 3 6 9 12 15 Year 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 Note: Rates are age standardised to the Australian population as at 30 June 2001. Data are reported by place of usual residence and year of diagnosis. Uterine cancer is defined by the ICD-0-2 codes of C54 Source: Queensland Cancer Registry, Queensland Health and Queensland Cancer Fund. Generated by Epidemiology Services Unit, Queensland Health For more information: Health Status Indicators for Queensland (h...

305 Volume 17, Number 4 ORIGINAL ARTICLE ORIGINAL ARTICLE Radiation Medicine: Vol.17 No.4, 305–309 p.p., 1999 Angiographic Changes in Uterine Cervical Cancer during the Course of Transarterial Infusion Chemotherapy Hidekazu Saitoh,* Yasushi Nagata,* Michihide Mitsumori,* Masaki Kokubo,* and Masahiro Hiraoka* Purpose: To assess the correlation between angiographic findings, tumor stage, tumor size, histological type, and the effect of transcatheter arterial infusion (TAI) chemotherapy in patients with uterine cervical cancer. Materials and Methods: Thirty-three patients with untreated cervical cancer underwent two cycles of TAI. Changes in angiographic findings and other clinical and imaging data were assessed using the ? 2 test, multivariate analysis, and the two-sample t-test. Results: The group with parametric involvement included more ...

SUSWORO ET AL 2 RADIATION MEDICINE R E V I E W Radiation Medicine: Vol. 22 No. 1, 2–5 p.p., 2004 HDR Interstitial Perineal Implant for Locally Advanced or Recurrent Uterine Cervix Cancer Raden Susworo, Nana Supriana, and Irwan Ramli Purpose: To evaluate whether high-dose-rate (HDR) interstitial perineal implants can effectively eradicate residual tumor or recurrent tumor in uterine cervix cancer after complete radiation treatment. Materials and Methods: This method of treatment was commenced in January 2002, and four advanced stage and four uterine cervix cancer ( UCC) recurrences were admitted for this study. All untreated stage II bulky mass and IIIB patients received 50 Gy external beam radiotherapy (EBR) to the whole pelvis prior to the interstitial perineal implant. No EBR was given to recurrent UCC. Brachytherapy was delivered using Martinez ...

Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer Dong Choon Park, a,1 Jae Hoon Kim, a Young Ok Lew, a Dae Hoon Kim, a, * and Sung Eun Namkoong b a Department of Obstetrics and Gynecology, Saint Vincent’s Hospital, The Catholic University of Korea, Suwon, Korea b Kang Nam Saint Mary’s Hospital, The Catholic University of Korea, Seoul, Korea Received 20 November 2002 Abstract Objectives . The toxicity and effectivity of intravenous paclitaxel and cisplatin as neoadjuvant chemotherapy were assessed in cervical cancer patients. Patients and methods . Forty-three consecutive patients affected by International Federation of Gynecology and Obstetrics (FIGO) stage IB2 to IIB were treated with paclitaxel 60 mg/m 2 that was administered intravenously over ...

Cancer Mortality by Remoteness Category in Queensland Uterine cancer 0 3 6 9 12 15 18 21 Rate per 100,000 population Avg No. per Year Mortality of Uterine cancer among Females, by ARIA Category, Queensland, Five Year Average, 1997 to 2001 2.7 35 Highly accessible ARIA Category 2.6 6 Moderately accessible 1.8 3 Accessible 5.4 2 Remote 9.5 2 Very remote Note: Rates are age standardised to the Australian population as at 30 June 2001. Numbers and rates are averaged over five years, and based on place of usual residence at time of diagnosis. The range shown by the orange line corresponds to the 95% confidence interval for the estimated rate. Uterine cancer is defined by the ICD-0-2 codes of C54 . Source: ...

Cancer Incidence by Remoteness Category in Queensland Uterine cancer 0 5 10 15 20 25 30 35 40 Rate per 100,000 population Avg No. per Year Incidence of Uterine cancer among Females, by ARIA Category, Queensland, Five Year Average, 1997 to 2001 16.0 199 Highly accessible ARIA Category 13.4 29 Moderately accessible 16.4 28 Accessible 16.3 6 Remote 20.3 4 Very remote Note: Rates are age standardised to the Australian population as at 30 June 2001. Numbers and rates are averaged over five years, and based on place of usual residence at time of diagnosis. The range shown by the orange line corresponds to the 95% confidence interval for the estimated rate. Uterine cancer is defined by the ICD-0-2 codes of C54 ...

REG-8 REG-7 REG-6 REG-5 REG-4 REG-3 REG-2 REG-1 WYOMING ORLEANS NIAGARA GENESEE ERIE CHAUTAUQUA CATTARAUGUS ALLEGANY YATES *** WAYNE STEUBEN SENECA *** SCHUYLER *** ONTARIO MONROE LIVINGSTON CHEMUNG TOMPKINS ST. LAWRENCE OSWEGO ONONDAGA ONEIDA MADISON LEWIS *** JEFFERSON HERKIMER CORTLAND CAYUGA TIOGA CHENANGO BROOME WASHINGTON WARREN SCHOHARIE SCHENECTADY SARATOGA RENSSELAER OTSEGO *** MONTGOMERY *** HAMILTON GREENE FULTON FRANKLIN ESSEX *** DELAWARE COLUMBIA CLINTON ALBANY WESTCHESTER ULSTER SULLIVAN ROCKLAND PUTNAM ORANGE DUTCHESS RICHMOND QUEENS NEW YORK KINGS BRONX SUFFOLK NASSAU INCIDENCE RATE 0 1 ...

UTERINE CANCER IN MARIN COUNTY 1995-1999 0 5 10 15 20 25 30 35 40 45 Marin SF Bay Area Urban CA Incidence Mortality * In general, corpus uteri cancer is more common among women of white non-Hispanic ethnicity than among women of other ethnicities. The small size of the African-American, Hispanic, and Asian populations in Marin County prevents the calculation of stable incidence rates for these populations. For this reason, and because the incidence of corpus uteri cancer varies by race/ethnicity, the above data includes only white non-Hispanic Marin County residents. Age-adjusted rates of corpus uteri cancer among individuals of white-non- Hispanic race/ethnicity, 1995-1999: Incidence Rates: Marin: 34.4/100,000 San Francisco Bay Area: 26.6/100,000 Urban California: ...

For Internal Use Only. Not For Use With The Public. This material is intended for insurance informational purposes only and is not personal medical advice for clients. Prudential Financialand the Rock logo are registered service marks of The Prudential Insurance Company of America and its affiliates The Prudential Insurance Company of America 751 Broad Street, Newark, NJ 07102-3777 RX60 DOC IFS-A018915, Ed. 10/03, Exp. 04/05 Endometrial ( Uterine) Cancer Endometrial ( uterine ) cancer is diagnosed in almost 39,300 women/year in the U.S. Although cancer death rates have been declining since the 1930’s due primarily to earlier diagnosis, endometrial cancer still accounts for approximately 6,600 cancer deaths each year. It occurs most frequently in women between the ages of 50 and 70. Risk factors for endometrial cancer include: • menstrual irregularities • hypertension ...

© Kamla-Raj 2003 KEYWORDS Cervix smears; micronuclei; exfoliated urine cells ABSTRACT Cytogenetic damage was assessed using the (MN) test in urothelial cells and cervix smears of local cervix cancer patients since the genetic end-point screening for micronuclei provides a measure of both, chromosome breakage and loss. The MN data were grouped for stage-types of cancer, age-groups, age-at- marriage, parity levels and socio-economic status. A comparison of the results obtained from both the tissues has revealed that the percent frequency of MNd cells was elevated in urothelial cells except when the variable for age-groups of the patients was compared. If validated, the MN assay in urothelial cells may prove useful for screening programmes for cervix cancer as besides scoring effectively for cytogenetic damage, it utilizes a non-invasive process of sample collection. INTRODUCTION ...

Cancer Research and Treatment 2003;35(6):549-556 1 INTRODUCTION Photodynamic therapy (PDT) is principally a new method of treating malignant tumors, based on the use of photodynamical damage of tumor cells under a photochemical reaction (1~3). During the last several years, a whole range of dyes, such as Photofrin (Axcan Scandipharm Inc., Birmingham, AL), HPD (Beijing Institute of Pharmaceutical, Beijing, China), Photogem (TimTec Corp., Newark, DE), Benzoporphyrin derivative (QLT Inc., Vancouver, Canada), 5-aminolevulenic acid (PhotoCure Inc., Oslo, Norway) and others, have been used as photosen- sitizers for a wide range of malignant tumors, as well as non-malignant diseases (4~6). A tumor treated by PDT was resorbed, and gradually substituted by connecting tissues. The locality of photodynamic damage of a tumor is provided by the ability of a photosensitizer to accumulate in ...

Center for Environmental Health Studies (617) 482-9485 44 Farnsworth Street, Boston, MA 02210 http://www.jsi.com * Findings were statistically significant (strong evidence) + Evidence of a dose-response relationship (strongest evidence) Page 31 Cervical and Uterine Cancer and Exposure to Ionizing Radiation Summary: Moderate evidence has been recorded of a possible connection between cervical and uterine cancers and exposure to ionizing radiation. This evidence is based upon studies of nuclear workers and others exposed to ionizing radiation. The National Research Council’s has not determined whether the uterus is sensitive to ionizing radiation. Cervical and uterine cancers are not designated as “specified” cancers under the Energy Employees Occupational Illness Compensation Program Act. Historically, cervical cancer incidence ...

Low-cost technology for screening uterine cervical cancer V AdityaParashari, 1 VeenaSingh, 2 AshokSehgal, 3 Labani Satyanarayana, 4 PushpaSodhani, 4 &MadanM. Gupta 2 We report on an illuminated, low-cost (Rs 1500 (US$ 36)) magnifying device (Magnivisualizer) for detecting precancerous lesions of the uterine cervix. A total of 403 women attending a maternal and child health care clinic who had abnormal vaginal discharge and related symptoms were referred for detailed pelvic examination and visual inspection by means of the device after the application of 5% (v/v) acetic acid. Pap smears were obtained at the same time. The results were compared with those obtained using colposcopy and/or histology. The Magnivisualizer improved the detection rate of early cancerous lesions from 60%, for unaided visual inspection, ...

uterine cancer 1126 UTERINE CANCER A Service of the Long Beach V A M C Patient Education Series 1998 What Is This? Cancer of the lining of the uterus. It usually affects postmenopausal women ages 50-60. How Can I Know If I Have This? Early stages: Bleeding or spotting, especially after sexual intercourse. This often occurs after menstrual activity has ceased for 12 months or more. Enlarged uterus. Later stages: Spread to other organs, causing abdominal pain, chest pain and weight loss. What Causes This? Unknown. You Are More Likely To Get This If: Diabetes mellitus. Obesity. High blood pressure. Use of estrogen without also using progesterone. Family history of breast or ovarian cancer. History of uterine polyps, menstrual cycles without ovulation, ...

All-Ireland cancer statistics 1994-96 73 Uterine corpus 15. MALIGNANT CANCER OF THE UTERINE CORPUS ICD-O.2 C54 ICD-10 C54 ICD-9 182 This category includes the main body of the uterus, but excludes the cervix (ICD-10 code C53: Chapter 14) and unspecified parts of the uterus (C55). Key facts • Average of 299 new cases (60 deaths) per year, 1994-96. • 7th most common site for cancer incidence, and 14th most common cause of cancer deaths, in females. • Incidence rates below the EU average. Summary statistics Table 15.1 Incidence 1994-96 On average each year, 299 new cases of malignant cancer of the uterine corpus (body of uterus) were diagnosed in females, in Ireland as a whole. This was the seventh most common cancer site in females and more common than invasive cancer of the cervix. On average, ...

44 TABLE 21. ENDOMETRIAL ( UTERINE CORPUS) CANCER INCIDENCE BY COUNTY, WHITE FEMALES, NEW JERSEY - 1986-1996 1 COUNTY 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 (Prelim.) No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate Atlantic 24 19.9 26 22.6 23 17.4 15 14.2 27 22.9 33 24.5 30 24.2 37 31.2 35 27.9 26 21.4 22 18.0 Bergen 123 20.6 136 24.1 121 20.6 115 20.2 98 16.7 161 29.2 135 23.9 125 22.3 139 24.6 126 22.6 138 23.9 Burlington 26 13.7 41 22.1 31 15.9 40 19.2 42 21.3 38 19.3 35 18.0 59 28.9 57 26.8 57 28.2 47 22.3 Camden 50 18.8 43 15.1 50 19.3 61 22.2 61 23.0 61 23.8 55 21.9 45 18.3 55 22.0 ...

45 ENDOMETRIAL ( UTERINE CORPUS) CANCER INCIDENCE BY COUNTY, BLACK FEMALES, NEW JERSEY - 1986-1990 AND 1991-1996 1 COUNTY 1986-1990 1991-1996 Number Rate Number Rate 2 2 Atlantic 13 11.4 21 13.4 Bergen 15 14.1 29 18.8 Burlington 11 10.1 28 20.9 Camden 25 13.6 35 14.4 Cumberland 15 30.0 6 8.3 Essex 115 14.7 146 14.6 Gloucester 5 8.9 10 14.0 Hudson 25 15.6 44 20.1 Mercer 21 14.3 28 14.2 Middlesex 8 9.5 24 18.4 Monmouth 21 16.3 27 15.0 Morris --- --- 8 19.1 Ocean --- --- 7 23.3 Passaic 19 14.8 29 15.6 Salem --- --- ...

Abstract. Lumican is a member of a small leucine-rich proteoglycan (SLRP) family and is reported to be over- expressed during the wound healing process of the cornea, and ischemic and reperfused heart. In the carcinomatous tissues, lumican is overexpressed in human breast and pancreatic cancer tissues. In the present study, we aimed to clarify the expression of lumican mRNA and its protein in human cervical cancer cell lines (CaSki, ME-180 and HeLa cells) and their localization in normal and cancerous human cervical tissues. Reverse transcription-polymerase chain reaction and Western blot analysis revealed the expression of lumican mRNA and its protein in CaSki, ME-180 and HeLa cells. No or weak immunoreactivity of the lumican protein was observed in stroma but not in squamous and ductal cells of non-cancerous uterine cervical tissues. In 21 of 28 (75%) cervical cancer cases, the lumican protein ...

Abstract. We previously reported satisfactory therapeutic results of cisplatin-based cyclic balloon-occluded arterial infusion chemotherapy (BOAI) as neoadjuvant chemotherapy, which enabled treatment by hysterectomy in patients with advanced cervical cancer. We also reported expression of apoptosis among these patients and determined that the bax gene is related to this apoptosis. In the present study, we investigated the relationship between the effectiveness of BOAI therapy and expression of apoptosis regulatory genes and proteins in these cases. The subjects were 27 women with advanced cervical cancer classified as FIGO (International Federation of Gynecology and Obstetrics) stage III or higher who were admitted to the Department of Gynecology, Osaka City University Medical School Hospital between 2000 and 2003. All patients were treated by BOAI, and expression of cancer cell apoptosis was ...

uterine cancer 1146 UTERINE/ ENDOMETRIAL CANCER What is Uterine/ Endometrial Cancer ? Cancers that occur in the uterus (the hollow, pear-shaped organ in which a baby grows, also called the womb) may be from one of two sources. The most common one starts in the lining (endometrium) of the uterus. Facts: Uterine/ endometrial cancer is the fourth most common cancer affecting women. Approximately 37,000 new cases are diagnosed each year. This cancer usually occurs after reproductive years, between ages 50 and 70. Causes/Risk Factors: For uterine/ endometrial cancer : ( the cause is not entirely clear, but may be related to levels of estrogen in the woman?s body) Age: usually women over 50 History of endometrial hyperplasia: increase in number of ...

B reast ca ncer. Ov arian ca ncer. C o l o rectal ca ncer. En dometrial (ut erine) ca ncer. M e l a n o m a . * A re you at risk? You could be if you have: r A personal or family history of ca ncer , di agnosed before the age of 50 (early onset) r A history of more than one type of ca ncer in yourself or another family member r Clusters or patterns of cancers in the family (for example, having both breast and ovarian ca ncer, co lorectal and endometrial ca ncer , or melanoma and pancreatic ca ncer) If you have one or more of these risk factors, hereditary ca ncer te sting may be right for you. Having ca ncer in your family could increase your risk. Hereditary ca ncer te sting helps you discover and understand your own risk now — so you can take steps to reduce that risk now . For more ...

B reast ca ncer. Ov arian ca ncer. C o l o rectal ca ncer. En dometrial (ut erine) ca ncer. M e l a n o m a . * A re you at risk? You could be if you have: r A personal or family history of ca ncer, di agnosed before the age of 50 (early onset) r A history of more than one type of ca ncer in yourself or another family member r Clusters or patterns of cancers in the family (for example, having both breast and ovarian ca ncer, co lorectal and endometrial ca ncer, or melanoma and pancreatic ca ncer) If you have one or more of these risk factors, hereditary ca ncer te sting may be right for you. Having ca ncer in your family could increase your risk. Hereditary ca ncer te sting helps you discover and understand your own risk now — so you can take steps to reduce that risk now. For ...